Post-earnings recap
Reported
Tue, Mar 12, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that Amicus Therapeutics exceeded expectations on EPS, which contributed to a positive stock reaction, with shares rising 4.38%. However, the lack of revenue data and forward guidance may leave investors cautious. Overall, the company appears to be making progress in its operations, but clarity on future performance is needed.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | +30.94% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, particularly regarding EPS. They emphasized ongoing efforts to develop their product pipeline.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.